Loading...

BCRX BIOCRYST PHARMACEUTICALS INC Product Launches 8-K Filing

BCRY

BCRX

BIOCRYST PHARMACEUTICALS INC

(BCRX)

2025 8-K

Show Summary

Summary

Financial Statements

Stock Purchase Agreement

Clinical Trials

New Product Launches

Financial Statements

Management Changes

CFO Resignation

Financial Results

Investor Conference

Q3 Financial Results

Trial Enrollment

Financial Results and Busin...

Annual Meeting Approval

Financial Results Announcement

Financial Results Announcement

By-Laws Amendment

Financial Results

Departure of Directors

Commercialization Agreement...

Regulation FD Disclosure

License Agreement for Avora...

Financial Results Announcement

Clinical Trial Enrollment

Financial Results and Busin...

Annual Meeting Approval of ...

Financial Results and Busin...

External Links:

On May 14, 2025, BioCryst Pharmaceuticals announced that the FDA accepted their application for ORLADEYO® oral granules for pediatric patients aged 2 to 11 with hereditary angioedema and granted priority review, targeting a decision by September 12, 2025.

AI Assistant

BIOCRYST PHARMACEUTICALS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.